A comprehensive review of integrative pharmacology-based investigation: A paradigm shift in traditional Chinese medicine by authors Haiyu Xu, Yanqiong Zhang, Ping Wang, Junhong Zhang, Hong Chen, Luoqi Zhang, Xia Du, Chunhui Zhao, Dan Wu, Feng Liu, Hongjun Yang and Changxiao Liu (https://doi.org/10.1016/j.apsb.2021.03.024). This review focuses on the presentation of the novel concept and the main research contents, methodologies and applications of integrative pharmacology-based traditional Chinese medicine.
Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China by authors Zhiqiang Wang, Zhibo Zhang, Yong Li, Li Sun, Dezhen Peng, Danyu Du, Xian Zhang, Luwei Han, Liwen Zhao, Ligong Lu, Hongzhi Dud, Shengtao Yuan and Meixiao Zhan (https://doi.org/10.1016/j.apsb.2021.03.005). This study comprehensively evaluated SH1573, a novel mIDH2 inhibitor, in terms of pharmacodynamics, pharmacokinetics, and toxicological properties, which made this drug enter phase I clinical trials successfully.
Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase by authors Quanjie Li, Dongrong Yi, Xiaobo Lei, Jianyuan Zhao, Yongxin Zhang, Xiangling Cui, Xia Xiao, Tao Jiao, Xiaojing Dong, Xuesen Zhao, Hui Zeng, Chen Liang, Lili Ren, Fei Guo, Xiaoyu Li, Jianwei Wang and Shan Cen (https://doi.org/10.1016/j.apsb.2021.02.011). The authors report that RAI-S-37 (corilagin) acts as a non-nucleoside inhibitor of SARS-CoV-2 RdRp, binds directly to RdRp, effectively inhibits the polymerase activity in both cell-free and cell-based assays, fully resists the proofreading activity and potently inhibits SARS-CoV-2 infection in vitro.
Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer by authors Shipeng He, Junhui Ma, Yuxin Fang, Ying Liu, Shanchao Wu, Guoqiang Dong, Wei Wang and Chunquan Sheng (https://doi.org/10.1016/j.apsb.2020.11.022). The authors demonstrate for the first time "suicide" cleavage of MDM2: a homo-PROTAC strategy possessing effective in vitro and in vivo antitumor activities. The approach may offer an opportunity to overcome the bottleneck of the dose-related adverse effects of MDM2?P53 inhibitors in the development of clinical anticancer agents.
Other articles published in the issue include:
Editorials Celebratory message from the Editor-in-Chief on the 10th anniversary of APSB
Jian-dong Jiang
https://doi.org/10.1016/j.apsb.2021.05.025
A message from the Co-Editor-in-Chief
Xinxin Ding
https://doi.org/10.1016/j.apsb.2021.05.026
Reviews Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment
Qin Xie, Jian Ding, Yi Chen
https://doi.org/10.1016/j.apsb.2021.03.027
The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment
Hong Zhang, Liwu Fu
https://doi.org/10.1016/j.apsb.2021.02.008
The Ca2+-activated chloride channel ANO1/TMEM16A: An emerging therapeutic target for epithelium-originated diseases?
Yani Liu, Zongtao Liu, KeWei Wang
https://doi.org/10.1016/j.apsb.2020.12.003
Nature?s marvels endowed in gaseous molecules I: Carbon monoxide and its physiological and therapeutic roles
Xiaoxiao Yang, Wen Lu, Christopher P. Hopper, Bowen Ke, Binghe Wang
https://doi.org/10.1016/j.apsb.2020.10.010
The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition
Michael A. Serwetnyk, Brian S.J. Blagg
https://doi.org/10.1016/j.apsb.2020.11.015
Insight into chemical basis of traditional Chinese medicine based on the state-of-the-art techniques of liquid chromatography-mass spectrometry
Yang Yu, Changliang Yao, De-an Guo
https://doi.org/10.1016/j.apsb.2021.02.017
Extracellular vesicle activities regulating macrophage- and tissue-mediated injury and repair responses
Qian Hu, Christopher J. Lyon, Jesse K. Fletcher, Wenfu Tang, Meihua Wan, Tony Y. Hu
https://doi.org/10.1016/j.apsb.2020.12.014
Original articles Identification of ferroptosis as a novel mechanism for antitumor activity of natural product derivative a2 in gastric cancer
Ying Liu, Zan Song, Yajie Liu, Xubin Ma, Wang Wang, Yu Ke, Yichao Xu, Dequan Yu, Hongmin Liu
https://doi.org/10.1016/j.apsb.2021.05.006
Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice
Lili Ding Qiaoling Yang, Eryun Zhang, Yangmeng Wang, Siming Sun, Yingbo Yang, Tong Tian, Zhengcai Ju, Linshan Jiang, Xunjiang Wang, Zhengtao Wang, Wendong Huang, Li Yang
https://doi.org/10.1016/j.apsb.2021.03.038
Mitochondrial protein IF1 is a potential regulator of glucagon-like peptide (GLP-1) secretion function of the mouse intestine
Ying Wang, Jiaojiao Zhang, Xinyu Cao, Yaya Guan, Shuang Shen, Genshen Zhong, Xiwen Xiong, Yanhong Xu, Xiaoying Zhang, Hui Wang, Jianping Ye
https://doi.org/10.1016/j.apsb.2021.02.002
LIX1-like protein promotes liver cancer progression via miR-21- 3p-mediated inhibition of fructose-1,6-bisphosphatase
Jie Zou, Xiaoyun Zhu, Dejuan Xiang, Yanqiu Zhang, Jie Li, Zhigui Su, Lingyi Kong, Hao Zhang
https://doi.org/10.1016/j.apsb.2021.02.005
HYD-PEP06 suppresses hepatocellular carcinoma metastasis, epithelial-mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K/AKT and WNT/β-catenin signaling activation
Wei Tian, Jiatong Li, Zhuo Wang, Tong Zhang, Ying Han, Yanyan Liu, Wenfeng Chu, Yu Liu, Baofeng Yang
https://doi.org/10.1016/j.apsb.2021.03.040
Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment
Jiashu Xie, Zhengqiang Wang
https://doi.org/10.1016/j.apsb.2021.03.028
From Vietnamese plants to a biflavonoid that relieves inflammation by triggering the lipid mediator class switch to resolution
Tran Thi Van Anh, Alilou Mostafa, Zhigang Rao, Simona Pace, Stefan Schwaiger, Christian Kretzer, Veronika Temml, Carsten Giesel, Paul M. Jordan, Rossella Bilancia, Christina Weinigel, Silke Rummler, Birgit Waltenberger, Tran Hung, Antonietta Rossi, Hermann Stuppner, Oliver Werz, Andreas Koeberle
https://doi.org/10.1016/j.apsb.2021.04.011
New guaiane-type sesquiterpenoid dimers from Artemisia atrovirens and their antihepatoma activity
Lihua Su, Xintian Zhang, Yunbao Ma, Changan Geng, Xiaoyan Huang, Jing Hu, Tianze Li, Shuang Tang, Cheng Shen, Zhen Gao, Xuemei Zhang, Ji-Jun Chen
https://doi.org/10.1016/j.apsb.2020.12.006
Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in rats
David Dahlgren, Tobias Olander, Markus Sjöblom, Mikael Hedeland, Hans Lennernäs
https://doi.org/10.1016/j.apsb.2020.12.019
Extensive expansion of the chemical diversity of fusidane-type antibiotics using a stochastic combinational strategy
Xiaojun Song, Jianming Lv, Zhiqin Cao, Huiyun Huang, Guodong Chen, Takayoshi Awakawa, Dan Hu, Hao Gao, Ikuro Abe, Xinsheng Yao
https://doi.org/10.1016/j.apsb.2020.12.007
Short communication Development of a highly-specific 18F-labeled irreversible positron emission tomography tracer for monoacylglycerol lipase mapping
Zhen Chen, Wakana Mori, Jian Rong, Michael A. Schafroth, Tuo Shao, Richard S. Van, Daisuke Ogasawara, Tomoteru Yamasaki, Atsuto Hiraishi, Akiko Hatori, Jiahui Chen, Yiding Zhang, Kuan Hu, Masayuki Fujinaga, Jiyun Sun, Qingzhen Yu, Thomas L. Collier, Yihan Shao, Benjamin F. Cravatt, Lee Josephson, Ming-Rong Zhang, Steven H. Liang
https://doi.org/10.1016/j.apsb.2021.01.021
INFORMATION:
The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association.
For more information please visit https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/
Editorial Board: https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/editorial-board
APSB is available on ScienceDirect (https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b).
Submissions to APSB may be made using Editorial Manager® (https://www.editorialmanager.com/apsb/default.aspx).
CiteScore: 10.5
Impact Factor: 7.097
5-Year Impact Factor: 7.865
Source Normalized Impact per Paper (SNIP): 2.210
SCImago Journal Rank (SJR): 1.792
ISSN 2211-3835
Acta Pharmaceutica Sinica B Volume 11, Issue 6 Publishes:
https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b/vol/11/issue/6
Special Issue: Celebrating 10 Years of Acta Pharmaceutica Sinica B (APSB)
